Published • loading... • Updated
FDA Clears Unixell's Stem Cell Therapy for Parkinson's
Summary by DistilINFO Publications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Clears Unixell's Stem Cell Therapy for Parkinson's
What Is UX-DA003? The US Food and Drug Administration (FDA) has cleared clinical trials for UX-DA003, a new experimental stem cell therapy for Parkinson’s disease. Unixell Biotechnology developed the treatment. This clearance allows the company to begin human testing in the United States — a major regulatory milestone in the global race to find disease-modifying therapies for Parkinson’s. UX-DA003 is an off-the-shelf, donor-derived therapy. Cons…
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
